TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
The Origin Story of Blue Sphere
Blue sphere was founded, I think in 18. Officially in 2018. You've been with the company since early 21. We're in 2023. The technology that we use for discovering T-cell receptors and the initial clinical indication was born out of two brothers who are both at the University of Pittsburgh. UPMC has its own investment fund called UPMC enterprises. They are sold, they are our sole investor and have invested over $100 million into our company.
Transcript
Play full episode
